Oncology Central

Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role


With a worldwide incidence of 263,900 cases and 128,000 deaths from oral cavity and lip cancer in 2008, squamous cell carcinoma of the head and neck (SCCHN) is one of the most common cancers and a major cause of cancer-related deaths [1]. SCCHN comprises a wide spectrum of neoplasms, such as cancers of the lip, oral cavity, larynx, pharynx and paranasal sinuses. National and international reports on cancer statistics on oral cavity and lip cancer, which often do not account for these other cancers, are therefore, likely to underestimate the magnitude of problems associated with SCCHN.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.